Rxsight Inc (RXST) Stock Price, Quote & News

Company Profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 521 7830

Website: rxsight.com

Address:

100 Columbia, Aliso Viejo, United States

drockafeller Jul. 16 at 8:07 PM

$RXST New CEO and current one moving to a CMO role... Thoughts everyone?

0 · Reply

npcpaperboy Jul. 16 at 7:49 PM

$RXST last show

0 · Reply

TickrTalk0007 Jul. 16 at 4:21 AM

$TARS Chief Commercial Officer left for a penny stock $RXST . Why does it say about TARS?😂

1 · Reply

OPmoney Jul. 15 at 1:06 PM

$RXST Missed the Pre-Announced / confrims what the Doc's office had stated on headcount. With a Colab and +Rev's no help to PPS, it's early days. Boomers will be running to fix cataracts in LARGE Numbers. $STAA is pretty well flat Myopes can't see the writing on the wall, "very auspicious"

0 · Reply

OPmoney Jul. 15 at 12:24 PM

$RXST PSA part 2: YAG LASER (to remove scar tissue post LAL implant) CAUSES FLOATERS. This is a big ask - having done Vitrectomy to remove YEARS of Floaters last year, is what caused the early-onset cataracts. The LAL implant disclosures do NOT tell you "floaters" will occur. KNOWING at time of YAG that FLOATERS WILL BE BACK - after all this work to get to 20/15 vision - was frustrating. At the moment the large .75" walking-stick-floater in mid-vision has vanished. One lite small floater is hanging around, it should vanish soon - then ALL CLEAR is expected.

1 · Reply

OPmoney Jul. 15 at 12:12 PM

$RXST PSA: LAL implants started for me APRIL 2nd. Final adj's on 7/14 - I NOW SEE 20/15 in BOTH EYES. 2 x Lock-in appts due in next weeks. Stock-wise price is down from $6.64 while Doc's office saying headcount to RXST LAL patients has increased TEN FOLD. Next ER should tell the tale - I did not see many/any wearing the same Dark issue glasses as me since April. Overall GOOD TO KNOW : 1) "EVERYONE GETS DRY EYE" - you must be proactive to prevent this 2) "EVERYONE GETS SCAR TISSUE" - Doc will use YAG laser to remove 3) YAG LASER CAUSES DRY EYE - DO NOT LEAVE DOC'S OFFICE WITHOUT PREDNISONE and plenty of Refresh Drops 4) NO PREDNISONE POST YAG LASER WILL DELAY ADJUSMENTS - make sure your doc is on top of this 5)NO ADJUSTMENTS WILL BE MADE WITH DRY EYE 7) It is frustrating to have to wait FOUR MONTHS to complete, it is WORTH IT.

0 · Reply

upupandgetpaid Jul. 10 at 3:48 PM

$RXST I'm gonna set an alert for new 52-week lows and just wait

0 · Reply

upupandgetpaid Jul. 7 at 1:02 PM

$RXST Do you all feel their revenue miss was significant? Were people investing here hoping for better results?

4 · Reply

jtstox Jul. 6 at 9:42 PM

$RXST reads all good to me nice low vol dip buy

0 · Reply

upupandgetpaid Jul. 6 at 8:57 PM

$RXST so they are partnering with Alcon on a project....why the drop? I see this as a positive although not an immediate revenue stream ....

1 · Reply

RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed

TARS

Jul 15, 2026, 4:15 PM EDT - 5 days ago

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

Jul 8, 2026, 12:00 PM EDT - 12 days ago

Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

2026-07-07T19:50:31.000Z - 13 days ago

RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M

2026-07-07T19:50:11.000Z - 13 days ago

RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M

2026-07-07T19:40:16.000Z - 13 days ago

RxSight price target lowered to $6.50 from $7.50 at Jefferies

Jul 7, 2026, 3:05 PM EDT - 13 days ago

The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

2026-07-07T16:55:16.000Z - 13 days ago

RxSight price target lowered to $6.50 from $8 at BofA

Jul 7, 2026, 8:00 AM EDT - 14 days ago

RxSight Transcript: Investor update

Jul 7, 2026, 8:00 AM EDT - 14 days ago

RxSight Press release: Investor update

2026-07-06T20:30:16.000Z - 14 days ago

Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs

ALC

2026-07-06T20:25:22.000Z - 14 days ago

Alcon, RxSight announce collaboration to develop adjustable PCIOLs

ALC

Jul 6, 2026, 4:15 PM EDT - 14 days ago

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Jul 6, 2026, 4:15 PM EDT - 14 days ago

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

Jul 6, 2026, 7:00 AM EDT - 15 days ago

RxSight Slides: Investor presentation

Jul 2, 2026, 3:02 PM EDT - 18 days ago

Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

May 26, 2026, 1:00 PM EDT - 7 weeks ago

RxSight Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 19, 2026, 4:10 PM EDT - 2 months ago

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

May 13, 2026, 6:00 PM EDT - 2 months ago

RxSight Transcript: Bank of America Global Healthcare Conference 2026

2026-05-07T13:37:20.000Z - 2 months ago

RxSight price target lowered to $11 from $13 at Needham

2026-05-07T00:52:25.000Z - 2 months ago

RxSight reports Q1 adjusted EPS (19c), consensus (15c)

2026-05-07T00:51:25.000Z - 2 months ago

RxSight backs FY26 revenue view $120M-$135M, consensus $129.22M

May 6, 2026, 4:30 PM EDT - 2 months ago

RxSight Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

RxSight Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

RxSight Quarterly report: Q1 2026

May 6, 2026, 4:05 PM EDT - 2 months ago

RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

May 6, 2026, 7:00 AM EDT - 2 months ago

RxSight Slides: Corporate presentation

Apr 29, 2026, 4:10 PM EDT - 2 months ago

RxSight, Inc. to Present at the Bank of America Healthcare Conference

Apr 28, 2026, 8:00 AM EDT - 3 months ago

RxSight Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

RxSight Proxy statement: Proxy filing

Apr 22, 2026, 4:10 PM EDT - 3 months ago

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

Apr 16, 2026, 11:00 AM EDT - 3 months ago

RxSight Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 3 months ago

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

Apr 2, 2026, 4:10 PM EDT - 3 months ago

RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference

2026-03-09T11:16:16.000Z - 4 months ago

RxSight price target lowered to $9 from $10 at Stifel

2026-02-26T13:26:59.000Z - 5 months ago

RxSight price target lowered to $10 from $11 at Piper Sandler

2026-02-26T13:15:33.000Z - 5 months ago

RxSight price target raised to $9 from $8 at UBS

2026-02-25T21:49:05.000Z - 5 months ago

RxSight reports Q4 EPS (3c), consensus (20c)

2026-02-25T21:47:02.000Z - 5 months ago

RxSight sees FY26 revenue $120M-$135M, consensus $135.34M

Feb 25, 2026, 4:30 PM EST - 5 months ago

RxSight Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

RxSight Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

RxSight Earnings release: Q4 2025

Feb 11, 2026, 4:10 PM EST - 5 months ago

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

2026-01-30T11:45:23.000Z - 6 months ago

RxSight initiated with a Market Perform at William Blair

2026-01-20T11:52:30.000Z - 6 months ago

RxSight price target raised to $11 from $10 at Piper Sandler

Jan 13, 2026, 6:45 PM EST - 6 months ago

RxSight Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:00 AM EST - 6 months ago

RxSight Slides: Corporate presentation

2026-01-12T13:55:08.000Z - 6 months ago

RxSight new CFO will be ‘well received,’ says Morgan Stanley

Jan 11, 2026, 9:30 AM EST - 6 months ago

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

Jan 2, 2026, 4:05 PM EST - 7 months ago

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

Dec 22, 2025, 5:15 PM EST - 7 months ago

RxSight, Inc. Announces Chief Financial Officer Transition

Dec 3, 2025, 12:00 PM EST - 8 months ago

RxSight Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 4:05 PM EST - 8 months ago

RxSight, Inc. to Present at the Piper Sandler Healthcare Conference

Nov 5, 2025, 4:30 PM EST - 9 months ago

RxSight Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 9 months ago

RxSight Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 9 months ago

RxSight Earnings release: Q3 2025

Nov 5, 2025, 4:05 PM EST - 9 months ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:05 PM EDT - 9 months ago

RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 16, 2025, 4:05 PM EDT - 9 months ago

RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting

Sep 22, 2025, 4:24 AM EDT - 10 months ago

RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST

Sep 16, 2025, 5:06 PM EDT - 10 months ago

DEADLINE NEXT WEEK: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Contact the Firm Before September 22, 2025

Sep 14, 2025, 7:17 AM EDT - 11 months ago

RXST STOCK NEWS: RxSight, Inc. Investors Urged to Act by September 22 Court Deadline -- Contact BFA Law if You Suffered Losses

Sep 12, 2025, 8:18 AM EDT - 11 months ago

RXST SECURITIES NOTICE: Did RxSight, Inc. Mislead Investors? Contact BFA Law if You Lost Money on Your Investment

Sep 8, 2025, 10:45 AM EDT - 11 months ago

RxSight Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 6, 2025, 7:18 AM EDT - 11 months ago

RXST LAWSUIT NOTICE: Lose Money on RxSight, Inc.? Contact BFA Law Prior to September 22 Legal Deadline (NASDAQ:RXST)

Sep 4, 2025, 10:15 AM EDT - 11 months ago

RxSight Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 29, 2025, 7:07 AM EDT - 11 months ago

RXST SHAREHOLDERS: RxSight, Inc. Investors may have been Affected by Fraud – Contact BFA Law by September 22 Court Deadline (NASDAQ:RXST)

Aug 25, 2025, 4:05 PM EDT - 11 months ago

RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference

Aug 23, 2025, 7:08 AM EDT - 11 months ago

RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST)

Aug 13, 2025, 8:33 AM EDT - 1 year ago

RXSIGHT STOCK: Lose Money on Your RxSight, Inc. (NASDAQ:RXST) Investment? Contact BFA Law before the September 22 Legal Deadline

drockafeller Jul. 16 at 8:07 PM

$RXST New CEO and current one moving to a CMO role... Thoughts everyone?

0 · Reply

npcpaperboy Jul. 16 at 7:49 PM

$RXST last show

0 · Reply

TickrTalk0007 Jul. 16 at 4:21 AM

$TARS Chief Commercial Officer left for a penny stock $RXST . Why does it say about TARS?😂

1 · Reply

OPmoney Jul. 15 at 1:06 PM

0 · Reply

OPmoney Jul. 15 at 12:24 PM

1 · Reply

OPmoney Jul. 15 at 12:12 PM

0 · Reply

upupandgetpaid Jul. 10 at 3:48 PM

$RXST I'm gonna set an alert for new 52-week lows and just wait

0 · Reply

upupandgetpaid Jul. 7 at 1:02 PM

$RXST Do you all feel their revenue miss was significant? Were people investing here hoping for better results?

4 · Reply

jtstox Jul. 6 at 9:42 PM

$RXST reads all good to me nice low vol dip buy

0 · Reply

upupandgetpaid Jul. 6 at 8:57 PM

$RXST so they are partnering with Alcon on a project....why the drop? I see this as a positive although not an immediate revenue stream ....

1 · Reply

TA_Kongen Jul. 6 at 8:21 PM

$RXST RXST - Alcon signs non-exclusive deal to co-develop adjustable PCIOLs w/ RxSight. RxSight gets $60M upfront, up to $140M in milestones, plus royalties. Watching

0 · Reply

jtstox Jul. 6 at 8:19 PM

$RXST buying the dip here

0 · Reply

jtstox Jul. 6 at 8:18 PM

$RXST alcon one of biggest eye care companies globally -

0 · Reply

upupandgetpaid Jun. 22 at 1:53 PM

$RXST I don't know this man but I'm counting on this......Ron Kurtz has already sold two prior eye surgery companies to Alcon and Abbott at 3–5x revenue multiples

0 · Reply

upupandgetpaid Jun. 22 at 1:32 PM

$RXST it's not just price , it is also volume :)

0 · Reply

upupandgetpaid Jun. 11 at 12:17 PM

$RXST if I only knew how to daytrade.....

1 · Reply

upupandgetpaid Jun. 8 at 5:42 PM

$RXST this board is dead.....

1 · Reply

upupandgetpaid Jun. 3 at 10:02 PM

$RXST can anyone explain the after hours jumps? Is it just algorithms trading blindly?

0 · Reply

upupandgetpaid Jun. 3 at 6:35 PM

$RXST If everything is red, nothing is red, right? Or is that magical thinking.....

0 · Reply

DrLukas19 Jun. 3 at 6:20 PM

$RXST Just started position. Negative enterprise value with cash burn of about $5-8 million per quarter. $210 million of cash. Risk/reward here is great IMO

0 · Reply

upupandgetpaid Jun. 2 at 2:12 PM

$RXST This stock is trading below it's cash value? That's kind of insulting....

1 · Reply

Market Cap	229.75M
Revenue (ttm)	134.48M
Net Income (ttm)	-38.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28.96%
Debt to Equity Ratio	0.00

Volume	747,300
Avg Vol	1,171,678
Day's Range	N/A - N/A
Shares Out	41.40M
Stochastic %K	71%
Beta	1.15
Analysts	Hold
Price Target	$8.43